Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 14, 2016 4:30 PM ET

Healthcare Equipment and Supplies

Company Overview of TriVascular Technologies, Inc.

Company Overview

TriVascular Technologies, Inc., a medical device company, develops and commercializes technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The company offers Ovation System, a stent graft platform for the treatment of AAA through minimally invasive endovascular aortic repair. Its ovation system components include arotic body, iliac limbs, and fill polymer. The company markets and sells its products through direct sales organizations in the United States, Germany, the United Kingdom, the Netherlands, and Canada, as well as through distributors or agents in other markets. TriVascular Technologies, Inc. was incorporated in 2007 and is headquartered in Santa ...

3910 Brickway Boulevard

Santa Rosa, CA 95403

United States

Founded in 2007

307 Employees



Key Executives for TriVascular Technologies, Inc.

Chairman, Chief Executive Officer and President
Age: 59
Total Annual Compensation: $450.0K
Co-Founder and Chief Technology Officer
Age: 54
Total Annual Compensation: $296.3K
Chief Financial Officer and Principal Accounting Officer
Age: 39
Total Annual Compensation: $356.2K
Compensation as of Fiscal Year 2014.

TriVascular Technologies, Inc. Key Developments

TriVascular Technologies, Inc.(NasdaqGS:TRIV) dropped from NASDAQ Composite Index

TriVascular Technologies, Inc. will be removed from Nasdaq Composite Index.

TriVascular Technologies, Inc. Amends and Restates Certificate of Incorporation

TriVascular Technologies, Inc. amended and restated Certificate of Incorporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, the company's certificate of incorporation was amended and restated in its entirety. Pursuant to the terms of the Merger Agreement, the bylaws of Merger Sub as in effect at the effective time of the Merger became the bylaws of TriVascular.

TriVascular Technologies, Inc., Special/Extraordinary Shareholders Meeting, Feb 03, 2016

TriVascular Technologies, Inc., Special/Extraordinary Shareholders Meeting, Feb 03, 2016, at 09:00 Pacific Standard Time. Location: offices of Arnold & Porter LLP, Three Embarcadero Center San Francisco, CA 94111 United States Agenda: To consider and vote upon, among other things, a proposal to adopt the Agreement and Plan of Merger.

Similar Private Companies By Industry

Company Name Region
Metamark Genetics, Inc. United States
Kypha Inc. United States
EndoScreen, LLC United States
Mirabilis Medical, Inc. United States
Megadyne Medical Products, Inc. United States

Recent Private Companies Transactions

October 26, 2015
Private Placement
August 18, 2015
Private Placement
August 4, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TriVascular Technologies, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at